Cabozantinib and immunotherapy for advanced stomach or bowel cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older
- Your daily functioning is good (ECOG 0–1)
- You have confirmed stomach/gastroesophageal/esophagus/colon cancer or liver cancer (hepatocellular carcinoma)
- Your cancer is stage 3 that can’t be fully removed or is stage 4, and you have measurable tumor on scans
- You can have required tumor biopsies for study testing (before treatment, and sometimes again later)
- If you have stomach/GEJ/esophagus cancer, you must have tried at least one standard treatment and your cancer got worse or you couldn’t tolerate it
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This study is testing a pill called cabozantinib for people with advanced liver cancer (HCC) that has grown despite prior treatment with atezolizumab (Tecentriq) and bevacizumab (Avastin). The goal is to see if cabozantinib can help shrink or slow the cancer.
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.